
Releases
GRAIL Faces Securities Fraud Lawsuit Following NHS-Galleri Trial Failure
Investors who suffered significant losses in GRAIL, Inc. are facing an August 4, 2026, deadline to seek lead plaintiff status in a newly filed securities fraud class action. The lawsuit alleges that senior executives misled shareholders about the clinical efficacy and design of the company’s landmark NHS-Galleri cancer screening trial.

.jpg)

























